Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction.
Olivier HuttinMasatake KobayashiJoão Pedro FerreiraStefano CoiroErwan BozecChristine Selton-SutyLaura FilipettiZohra LamiralPatrick RossignolFaiez ZannadNicholas GirerdPublished in: ESC heart failure (2021)
As the measurement of Gal3, P3NP, and ST2 results in marginal (even if significant) increase in the prediction of DD/LVH on top of routine evaluation, their systematic use should not be promoted in unselected healthy individuals to screen for preclinical DD. Further research is needed to determine whether a more personalized medicine approach combing proteomic and clinical scoring can amplify the added value of biomarkers to identify preclinical DD.
Keyphrases
- left ventricular
- cell therapy
- heart failure
- blood pressure
- acute myocardial infarction
- high throughput
- oxidative stress
- hypertrophic cardiomyopathy
- cardiac resynchronization therapy
- clinical practice
- aortic stenosis
- stem cells
- ejection fraction
- mesenchymal stem cells
- acute coronary syndrome
- single cell
- percutaneous coronary intervention
- label free
- transcatheter aortic valve replacement